PD
KYNB

Point72 (DIFC)’s Kyntra Bio KYNB Stock Holding History

Point72 (DIFC)’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$7 – 1801
2024
Q4 		$7 Hold
1
– – ﹤0.01% 1474
2024
Q3 		$6 Sell
1
-2,089
-100% -$31.5K ﹤0.01% 1387
2024
Q2 		$46.6K Buy
2,090
+1,839
+733% +$56.8K ﹤0.01% 1104
2024
Q1 		$14.7K Buy
+251
New +$10.8K ﹤0.01% 1328

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 (DIFC)'s KYNB Position: Q1 2025 in Review

Point72 (DIFC) sold out of Kyntra Bio (KYNB) in Q1 2025, closing a stake of 1 share — an estimated $7 sold.

Point72 (DIFC) first reported a position in KYNB in Q1 2024 and held it in 4 quarters. The position peaked at $46.6K in Q2 2024. 54 funds tracked by Wall St. Rank hold KYNB as of Q1 2025.

  • Point72 (DIFC) reported no remaining Kyntra Bio position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 1 Kyntra Bio share in Q1 2025, an estimated $7.
  • Point72 (DIFC) first reported a position in Kyntra Bio in Q1 2024 and held it in 4 quarters.
  • Point72 (DIFC)'s Kyntra Bio position peaked at $46.6K in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.